Metabolic reprogramming of tumor-associated macrophages using glutamine antagonist JHU083 drives tumor immunity in myeloid-rich prostate and bladder cancer tumors.
Praharaj M, Shen F, Lee AJ, Zhao L, Nirschl TR, Theodros D, Singh AK, Wang X, Adusei KM, Lombardo KA, Williams RA, Sena LA, Thompson EA, Tam A, Yegnasubramanian S, Pearce EJ, Leone RD, Alt J, Rais R, Slusher BS, Pardoll DM, Powell JD, Zarif JC.
Praharaj M, et al. Among authors: tam a.
Cancer Immunol Res. 2024 May 3. doi: 10.1158/2326-6066.CIR-23-1105. Online ahead of print.
Cancer Immunol Res. 2024.
PMID: 38701369